May MIMS update

We look at some of the recent changes to the medicines landscape, with new products as well as changes to indications New Products LetibotulinumtoxinA (Letybo) blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. This inhibition occurs according to the following sequence: heavy chain of toxin

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Students drop out over double dispensing: Guild
Next Double dispensing may not be as disastrous as portrayed